Transcriptome-Guided Identification of Drugs for Repurposing to Treat Age-Related Hearing Loss

• Published in: Biomolecules (Basel, Switzerland) Switzerland), 2022-03, Vol.12 (4), p.498
• Main Authors: Schubert, Nick M A, van Tuinen, Marcel, Pyott, Sonja J
• Format: Article
• Language: English
• Subjects: Age; age-related hearing loss; ageing; Aging; Animals; Cochlea; Cognitive ability; Dementia disorders; Drug development; Drug Repositioning; Drugs; Experiments; Gene expression; Genomes; hearing; Hearing loss; Inner ear; Mice; Mice, Inbred C57BL; Mutation; Older people; Organ of Corti; Oxidative stress; Pharmaceuticals; presbycusis; Presbycusis - drug therapy; Presbycusis - genetics; Presbycusis - metabolism; Quality control; RNA sequencing; Social interactions; Spiral ganglion; Spiral Ganglion - metabolism; Stria vascularis; Therapeutic targets; Transcription; Transcriptome - genetics; Transcriptomes; Transcriptomics
• ISSN: 2218-273X; 2218-273X
• DOI: 10.3390/biom12040498

Age-related hearing loss (ARHL) or presbycusis is a prevalent condition associated with social isolation, cognitive impairment, and dementia. Age-related changes in the cochlea, the auditory portion of the inner ear, are the primary cause of ARHL. Unfortunately, there are currently no pharmaceutical approaches to treat ARHL. To examine the biological processes underlying age-related changes in the cochlea and identify candidate drugs for rapid repurposing to treat ARHL, we utilized bulk RNA sequencing to obtain transcriptomes from the functional substructures of the cochlea-the sensorineural structures, including the organ of Corti and spiral ganglion neurons (OC/SGN) and the stria vascularis and spiral ligament (SV/SL)-in young (6-week-old) and old (2-year-old) C57BL/6 mice. Transcriptomic analyses revealed both overlapping and unique patterns of gene expression and gene enrichment between substructures and with ageing. Based on these age-related transcriptional changes, we queried the protein products of genes differentially expressed with ageing in DrugBank and identified 27 FDA/EMA-approved drugs that are suitable to be repurposed to treat ARHL. These drugs target the protein products of genes that are differentially expressed with ageing uniquely in either the OC/SGN or SV/SL and that interrelate diverse biological processes. Further transcriptomic analyses revealed that most genes differentially expressed with ageing in both substructures encode protein products that are promising drug target candidates but are, nevertheless, not yet linked to approved drugs. Thus, with this study, we apply a novel approach to characterize the druggable genetic landscape for ARHL and propose a list of drugs to test in pre-clinical studies as potential treatment options for ARHL.